PDE5A and pulmonary arterial hypertension: Further, in a recent clinical study of apelin in PAH patients, administration of apelin provided significant additive benefit, when given together with PDE5 inhibitor therapy, decreasing pulmonary vascular resistance, and increasing cardiac output and stroke volume (Brash et al., 2018).